Monte Rosa earns $50M milestone as Novartis starts Phase 2 Sjögren's study of MRT-6160

Monte Rosa Therapeutics, Inc.

Novartis initiated Phase 2a/b double-blind, placebo-controlled trial of VAV1 degrader MRT-6160 (DDY391) in Sjögren's disease; first patient visit triggers $50M payment to Monte Rosa.
Study tests up to 52 weeks of treatment; identifier NCT07737743; dose selection for Phase 3.
Monte Rosa eligible for up to $2.1B in development, regulatory, sales milestones from Novartis agreement.
Phase 1 data showed >90% VAV1 degradation in T cells with no serious adverse effects; additional Phase 2 studies expected.
Novartis funds Phase 2; Monte Rosa co-funds Phase 3 and shares 30% of U.S. profits/losses, plus ex-U.S. royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.